Overall rank by patents
#34,065
of 49,997 tracked assignees
USPTO PatentsView assignee record - 7 granted patents across 11 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: B64U (Unmanned Aerial Vehicles [UAV]; Equipment Therefor).
The verdict
According to USPTO PatentsView, Acsl ranks #34,065 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 11 technology areas.
USPTO PatentsView assignee plate
Corpus R34065 · Foreign Corporation #34,065 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: ACG Pam Pharma Technologies PVT. Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Acsl · this assignee
46 score
3D Lighting… · lowest
7 score
What this shows Acsl's Innovation Score is 45.9/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Acsl Ltd. is a focused PatentsView assignee: 11 CPC subclasses with 85.7% of grants classified under B64U (Unmanned Aerial Vehicles [UAV]; Equipment Therefor). Peak complete grant year is 2024 (3 grants) versus a trough of 1 in 2022. By volume, Acsl sits between ACG Pam Pharma Technologies PVT. Ltd. and Actuate Therapeutics Inc..
Acsl Ltd. shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ACG Pam Pharma Technologies PVT. Ltd.
7 patents
Achaogen, Inc.
7 patents
Acro Inc.
7 patents
Acrux DDS PTY Ltd
7 patents
Actega Metal Print GMBH
7 patents
Actian Netherlands B.V.
7 patents
Active Products Inc.
7 patents
Actuate Therapeutics Inc.
7 patents
Acsl Ltd.
7 patents
What this shows Acsl holds 7 patents at rank #34,058, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #34,058 in granted patent volume.
Other assignees with the most granted patents in Acsl's primary technology class.
Acsl's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
46 Top 22% higher than 78% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 1 | 14.3% |
| 2023 | 1 | 14.3% |
| 2024 | 3 | 42.9% |
| 2025partial year | 2 | 28.6% |
Top 11 of 11 technology areas
Overall rank by patents
#34,065
of 49,997 tracked assignees
45.9 out of 100
What to do with this data
Acsl Ltd.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.